UEEC 8-K
United Health Products, Inc. (UEEC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code) |
(
Registrant’s telephone number, including area code
___________________________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
N/A |
| N/A |
| N/A |
Item 7.01. Regulation FD Disclosure and Other Events.
On October 7, 2021, United Health Products, Inc. (the “Company”) issued a press release providing a business update along with the announcement of an investor information session scheduled for 9:00am Eastern Time on October 15, 2021. A copy of the press release is being furnished herewith as Exhibit 99.1,
During the investor information session, the Company will be making an investor presentation, a copy of which is being furnished herewith as Exhibit 99.2.
Investors wishing to participate in the information session may register by emailing the Company at [email protected] with the name, email address, phone number and country of residency of the participant.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | Description | |
| ||
| ||
104 |
| Cover Page Interactive Data File (formatted as Inline XBRL) |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on October 14, 2021.
United Health Products, Inc. |
| ||
| By: | /s/ Brian Thom | |
| Brian Thom Principal Executive Officer | ||
| By: | /s/ Kristofer Heaton | |
| Kristofer Heaton | ||
| Principal Financial Officer |
3 |
EXHIBIT 99.1
United Health Products Provides Business Update
Henderson, Nevada – October 7, 2021 – United Health Products, Inc. (OTCPK: UEEC), (UHP), developer, manufacturer and marketer of HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today provided an update on its regulatory approval application process and other business activities.
As part of its substantive review process to evaluate UHP’s PMA (Pre-market Approval) application, the FDA has requested details on certain elements of the HemoStyp manufacturing process. In keeping with industry best practices, UHP recently completed the implementation of an industry standard Good Manufacturing Practices (GMP) software tool and will be submitting a response to the FDA’s request later this month.
Separately, UHP’s registration statement was declared effective by the SEC on September 29th which permitted it to proceed towards closing of its previously announced stock purchase agreement with Triton Funds, who have agreed to invest between $4,000,000 and $6,000,000 in UHP’s common stock in one or more closings as may be requested by UHP from time to time. The registration statement registers shares purchased by Triton Funds for resale. These funds will enable the advancement of R&D, regulatory and commercial initiatives to bring a broad portfolio of HemoStyp formats to several geographic markets.
As part of its ongoing R&D effort, UHP recently produced a prototype form of HemoStyp material that is designed for trauma and surgical applications where its existing HemoStyp gauze material may not be suitable. Further in-vitro and animal testing is planned to advance potential FDA and other regulatory applications for use of this format.
UHP will host an update call on Friday October 15th at 9am ET, during which Brian Thom, UHP’s Chief Executive Officer, will provide an expanded summary of the Company’s priorities and ongoing product development efforts. The call will be “listen only” and can be accessed by registered participants using the Zoom link or dial-in number below:
https://us06web.zoom.us/j/5578590134
Meeting ID: 557 859 0134
Telephonic access: +1 929.205.6099 – Mtg ID 5578590134#
To register for this Zoom session, please email UHP at [email protected] and include your name, telephone number, email address and country of residency.
As previously disclosed, UHP’s Class III PMA application is currently in Substantive Review by the FDA. Receipt of a PMA will allow marketing of HemoStyp products for human surgical procedures. There can be no assurance that the PMA will be granted by the FDA.
About United Health Products -- UHP develops, manufactures and markets patented hemostatic products for the healthcare and wound care sectors. HemoStyp is an all-natural NORC product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental and veterinary markets and is focused on gaining approval to access the human surgical market.
For more information visit: www.unitedhealthproductsinc.com or contact the company at [email protected]
Investor relations: Philippe Niemetz 212 344-6464 [email protected]
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
EXHIBIT 99.2
